Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Ultragenyx Pharmaceutical Inc. (RARE : NSDQ)

• Company Description    Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Number of Employees: 1,371

• Price / Volume Information    Yesterday's Closing Price: $23.39 Daily Weekly Monthly 20 Day Moving Average: 1,715,696 shares Shares Outstanding: 98.49 (millions) Market Capitalization: $2,303.66 (millions) Beta: 0.39 52 Week High: $42.37 52 Week Low: $18.29 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -3.67% -8.37% 12 Week 1.52% -6.15% Year To Date 1.70% -5.22%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 60 Leveroni Court - Novato,CA 94949 USA ph: 415-483-8800 fax: 415-483-8810 ir@ultragenyx.com http://www.ultragenyx.com

• General Corporate Information    Officers Emil D. Kakkis - President and Chief Executive Officer Daniel G. Welch - Chairman Howard Horn - Executive Vice President; Chief Financial Officer; Theodore A. Huizenga - Senior Vice President and Chief Accounting Officer Deborah Dunsire - Director Peer Information Ultragenyx Pharmaceutical Inc. (CORR.) Ultragenyx Pharmaceutical Inc. (RSPI) Ultragenyx Pharmaceutical Inc. (CGXP) Ultragenyx Pharmaceutical Inc. (BGEN) Ultragenyx Pharmaceutical Inc. (GTBP) Ultragenyx Pharmaceutical Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 90400D108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/04/26 Share - Related Items Shares Outstanding: 98.49 Most Recent Split Date: (:1) Beta: 0.39 Market Capitalization: $2,303.66 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.24 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.63 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 32.04% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 3.44 EPS Growth vs. Year Ago Period: -17.20% vs. Previous Quarter: -42.64% Sales Growth vs. Year Ago Period: -2.36% vs. Previous Quarter: -34.30% ROE 03/31/26 - - 12/31/25 - -1,024.42 09/30/25 - -414.39 ROA 03/31/26 - -45.78 12/31/25 - -43.10 09/30/25 - -43.67 Current Ratio 03/31/26 - 2.02 12/31/25 - 2.48 09/30/25 - 1.89 Quick Ratio 03/31/26 - 1.85 12/31/25 - 2.34 09/30/25 - 1.74 Operating Margin 03/31/26 - -91.03 12/31/25 - -85.54 09/30/25 - -91.95 Net Margin 03/31/26 - -91.03 12/31/25 - -85.54 09/30/25 - -91.95 Pre-Tax Margin 03/31/26 - -90.38 12/31/25 - -84.84 09/30/25 - -91.40 Book Value 03/31/26 - -2.40 12/31/25 - -0.83 09/30/25 - 0.09 Inventory Turnover 03/31/26 - 2.14 12/31/25 - 2.22 09/30/25 - 2.05 Debt-to-Equity 03/31/26 - - 12/31/25 - - 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - - 12/31/25 - - 09/30/25 - 43.32

Powered by Zacks Investment Research ©